Publication:
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).

dc.contributor.authorCatenacci, Daniel V. T.
dc.contributor.authorKang, Yoon-Koo
dc.contributor.authorSaeed, Anwaar
dc.contributor.authorYamaguchi, Kensei
dc.contributor.authorQin, Shukui
dc.contributor.authorLee, Keun-Wook
dc.contributor.authorKim, In-Ho
dc.contributor.authorOh, Sang Cheul
dc.contributor.authorLi, Jin
dc.contributor.authorTurk, Haci M.
dc.contributor.authorTeixeira, Alexandra Carolina
dc.contributor.authorBorg, Christophe
dc.contributor.authorHitre, Erika
dc.contributor.authorUdrea, Anghel Adrian
dc.contributor.authorCardellino, Giovanni Gerardo
dc.contributor.authorGuardeno, Raquel
dc.contributor.authorMitra, Siddhartha
dc.contributor.authorYang, Yingsi
dc.contributor.authorEnzinger, Peter C.
dc.contributor.authorWainberg, Zev A.
dc.date.accessioned2021-11-30T20:59:13Z
dc.date.available2021-11-30T20:59:13Z
dc.date.issued2021-05-01T00:00:00Z
dc.identifier.citationCatenacci D. V. T. , Kang Y., Saeed A., Yamaguchi K., Qin S., Lee K., Kim I., Oh S. C. , Li J., Turk H. M. , et al., -FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).-, JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.doi10.1200/jco.2021.39.15_suppl.4010
dc.identifier.urihttp://hdl.handle.net/20.500.12645/29666
dc.identifier.wosWOS:000708120602112
dc.titleFIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).
dc.typeArticle
dspace.entity.typePublication
local.avesis.id09ff4e89-ff5b-4ecc-ac8d-a5abb22be087
local.publication.isinternational1
Files